HK Stock Market Move | REMEGEN (09995) rose more than 6% during trading hours. TaiTaiXipu has been included in the "Immune System Drugs" section of the 2026 National Essential Medicines List.

REMEGEN (09995) surged over 6% during trading hours, reaching a 6.16% increase at the time of publication, closing at 87 Hong Kong dollars with a trading volume of 2.68 billion Hong Kong dollars. On the news front, according to REMEGEN official Weibo account, on July 9, three government departments including the National Health Commission, National Administration of Traditional Chinese Medicine, and National Center for Disease Control jointly released the "National Essential Medicines List (2026 edition)". The company's independently developed global pioneering BLyS/APRIL dual-target fusion protein drug, Taetuxipu (sterile powder for injection: 80mg), has been included in the category of "immunomodulatory drugs". The new version of the list includes 2 domestic Class I innovative biological drugs, with Taetuxipu being one of them. Taetuxipu, as one of the two domestic Class I innovative biological drugs included in the essential medicines list this time, relies on its global pioneering dual-target mechanism to simultaneously inhibit the overexpression of the cell factors BLyS and APRIL, treating a range of B cell-mediated autoimmune diseases. It has been approved for indications including systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjgren's syndrome, and IgA nephropathy (pre-filled syringe) for a total of 5 indications, with systemic lupus erythematosus and generalized myasthenia gravis already included in the national medical insurance list.